About Natus Medical Incorporated (NASDAQ:BABY)
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders. The Company's product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology, as well as newborn care products, such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, incubators to control the newborn's environment, and software systems for managing and tracking disorders and diseases for public health laboratories. The Company is organized into three strategic business units: Neurology, Newborn Care and Otometrics.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Advanced Medical Equipment & Technology
- Sub-Industry: Health Care Equipment
- Symbol: NASDAQ:BABY
- CUSIP: 63905010
- Web: www.natus.com
- Market Cap: $1.31 billion
- Outstanding Shares: 32,528,000
- 50 Day Moving Avg: $37.32
- 200 Day Moving Avg: $36.10
- 52 Week Range: $31.65 - $43.85
Sales & Book Value:
- Trailing P/E Ratio: 69.67
- Foreward P/E Ratio: 20.30
- P/E Growth: 1.07
- Annual Revenue: $445.49 million
- Price / Sales: 2.94
- Book Value: $13.11 per share
- Price / Book: 3.07
- EBITDA: $48 million
- Net Margins: 4.20%
- Return on Equity: 12.09%
- Return on Assets: 8.06%
- Debt-to-Equity Ratio: 0.26%
- Current Ratio: 3.33%
- Quick Ratio: 2.52%
- Average Volume: 373,151 shs.
- Beta: 0.95
- Short Ratio: 6.68
Frequently Asked Questions for Natus Medical Incorporated (NASDAQ:BABY)
What is Natus Medical Incorporated's stock symbol?
Natus Medical Incorporated trades on the NASDAQ under the ticker symbol "BABY."
How were Natus Medical Incorporated's earnings last quarter?
Natus Medical Incorporated (NASDAQ:BABY) posted its quarterly earnings results on Wednesday, July, 26th. The company reported $0.34 EPS for the quarter, topping analysts' consensus estimates of $0.33 by $0.01. The business earned $122.20 million during the quarter, compared to analysts' expectations of $121.99 million. Natus Medical Incorporated had a return on equity of 12.09% and a net margin of 4.20%. Natus Medical Incorporated's quarterly revenue was up 27.3% on a year-over-year basis. During the same quarter last year, the company posted $0.39 earnings per share. View Natus Medical Incorporated's Earnings History.
When will Natus Medical Incorporated make its next earnings announcement?
What guidance has Natus Medical Incorporated issued on next quarter's earnings?
Natus Medical Incorporated issued an update on its FY17 earnings guidance on Wednesday, July, 26th. The company provided earnings per share (EPS) guidance of $1.70-1.75 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.70. The company issued revenue guidance of $505-510 million, compared to the consensus revenue estimate of $504.56 million.Natus Medical Incorporated also updated its Q3 guidance to $0.37-0.38 EPS.
Where is Natus Medical Incorporated's stock going? Where will Natus Medical Incorporated's stock price be in 2017?
3 brokerages have issued 1 year price targets for Natus Medical Incorporated's stock. Their predictions range from $48.00 to $48.00. On average, they anticipate Natus Medical Incorporated's share price to reach $48.00 in the next twelve months. View Analyst Ratings for Natus Medical Incorporated.
Who are some of Natus Medical Incorporated's key competitors?
Some companies that are related to Natus Medical Incorporated include Quidel Corporation (QDEL), Mazor Robotics Ltd - (MZOR), Accelerate Diagnostics (AXDX), ABAXIS (ABAX), Luminex Corporation (LMNX), LeMaitre Vascular (LMAT), Pacific Biosciences of California (PACB), GenMark Diagnostics (GNMK), ViewRay (VRAY), Accuray Incorporated (ARAY), Corindus Vascular Robotics (CVRS), Cogentix Medical (CGNT), Cytosorbents Corporation (CTSO), Harvard Bioscience (HBIO), Neovasc (NVCN), Viveve Medical (VIVE), IRIDEX Corporation (IRIX) and Edap Tms S.A. (EDAP).
Who are Natus Medical Incorporated's key executives?
Natus Medical Incorporated's management team includes the folowing people:
- Robert A. Gunst, Independent Chairman of the Board
- James B. Hawkins, President, Chief Executive Officer, Director
- Jonathan A. Kennedy, Chief Financial Officer, Executive Vice President, IR Contact Officer
- Austin F. Noll III, Vice President and General Manager - Neurology Strategic Business Unit
- D. Christopher Chung M.D., Vice President - Medical Affairs, Quality & Regulatory
- Doris E. Engibous, Independent Director
- Kenneth E. Ludlum, Independent Director
- William M. Moore Jr., Independent Director
- Barbara R. Paul M.D., Independent Director
Who owns Natus Medical Incorporated stock?
Natus Medical Incorporated's stock is owned by many different of institutional and retail investors. Top institutional investors include Diamond Hill Capital Management Inc. (1.63%), Nationwide Fund Advisors (0.98%), Strs Ohio (0.34%) and Eqis Capital Management Inc. (0.05%). Company insiders that own Natus Medical Incorporated stock include Austin Francis Noll III, Dong Chune Christopher Chung, Doris Engibous, James B Hawkins, Jonathan Kennedy, Ken Ludlum, Kenneth M Traverso, Robert A Gunst and William M Moore. View Institutional Ownership Trends for Natus Medical Incorporated.
Who sold Natus Medical Incorporated stock? Who is selling Natus Medical Incorporated stock?
Natus Medical Incorporated's stock was sold by a variety of institutional investors in the last quarter, including Nationwide Fund Advisors and Diamond Hill Capital Management Inc.. Company insiders that have sold Natus Medical Incorporated stock in the last year include Doris Engibous, Jonathan Kennedy, Robert A Gunst and William M Moore. View Insider Buying and Selling for Natus Medical Incorporated.
Who bought Natus Medical Incorporated stock? Who is buying Natus Medical Incorporated stock?
How do I buy Natus Medical Incorporated stock?
Shares of Natus Medical Incorporated can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Natus Medical Incorporated's stock price today?
MarketBeat Community Rating for Natus Medical Incorporated (NASDAQ BABY)MarketBeat's community ratings are surveys of what our community members think about Natus Medical Incorporated and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Natus Medical Incorporated stock can currently be purchased for approximately $40.20.
Consensus Ratings for Natus Medical Incorporated (NASDAQ:BABY) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Sell Rating, 1 Hold Rating, 1 Buy Rating|
|Consensus Rating:||Hold (Score: 2.00)|
|Consensus Price Target: ||$48.00 (19.40% upside)|Consensus Price Target History for Natus Medical Incorporated (NASDAQ:BABY)
Analysts' Ratings History for Natus Medical Incorporated (NASDAQ:BABY)
(Data available from 10/23/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|5/1/2017||Benchmark Co.||Reiterated Rating||Buy -> Buy||$55.00 -> $48.00||Medium|
|2/2/2017||Raymond James Financial, Inc.||Downgrade||Outperform -> Market Perform||N/A|
|12/16/2016||Off Wall Street||Initiated Coverage||Sell||N/A|
|4/21/2016||Roth Capital||Reiterated Rating||Buy||N/A|
Earnings History for Natus Medical Incorporated (NASDAQ:BABY)Earnings History by Quarter for Natus Medical Incorporated (NASDAQ BABY)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|7/26/2017||Q2 2017||$0.33||$0.34||$121.99 million||$122.20 million||View||N/A|
|4/26/2017||Q1 2017||$0.33||$0.30||$122.45 million||$124.70 million||View||N/A|
|2/1/2017||Q416||$0.53||$0.51||$107.58 million||$107.70 million||View||Listen|
|10/19/2016||Q316||$0.34||$0.39||$89.94 million||$90.90 million||View||Listen|
|7/20/2016||Q216||$0.36||$0.39||$92.71 million||$96.00 million||View||Listen|
|4/20/2016||Q116||$0.30||$0.34||$90.47 million||$87.30 million||View||Listen|
|1/27/2016||Q415||$0.46||$0.51||$100.88 million||$100.00 million||View||Listen|
|10/21/2015||Q315||$0.38||$0.39||$93.70 million||$94.60 million||View||Listen|
|7/22/2015||Q215||$0.32||$0.34||$90.83 million||$91.90 million||View||Listen|
|4/22/2015||Q115||$0.29||$0.31||$88.93 million||$89.40 million||View||Listen|
|1/28/2015||Q414||$0.38||$0.40||$93.28 million||$94.00 million||View||Listen|
|10/22/2014||Q314||$0.31||$0.33||$87.30 million||$89.90 million||View||Listen|
|7/23/2014||Q214||$0.26||$0.28||$84.85 million||$86.30 million||View||Listen|
|4/23/2014||Q114||$0.23||$0.26||$84.70 million||$85.60 million||View||Listen|
|1/29/2014||Q413||$0.32||$0.37||$89.12 million||$90.60 million||View||Listen|
|10/24/2013||Q313||$0.19||$0.30||$80.83 million||$85.40 million||View||Listen|
|8/1/2013||Q2 2013||$0.14||$0.21||$83.50 million||$82.30 million||View||Listen|
|5/20/2013||Q1 2013||$0.11||$0.15||$84.47 million||$85.80 million||View||Listen|
|2/28/2013||Q4 2012||$0.26||$0.29||$93.60 million||$90.50 million||View||Listen|
|11/7/2012||$0.14||$0.15||$81.37 million||$80.70 million||View||N/A|
Earnings Estimates for Natus Medical Incorporated (NASDAQ:BABY)
2017 EPS Consensus Estimate: $1.80
2018 EPS Consensus Estimate: $2.01
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Natus Medical Incorporated (NASDAQ:BABY)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Natus Medical Incorporated (NASDAQ:BABY)
Insider Ownership Percentage: 5.50%Insider Trades by Quarter for Natus Medical Incorporated (NASDAQ:BABY)
Institutional Ownership Percentage: 92.66%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|9/14/2017||Robert A Gunst||Director||Sell||4,400||$35.17||$154,748.00|| |
|8/14/2017||William M Moore||Director||Sell||3,000||$34.10||$102,300.00|| |
|6/15/2017||James B Hawkins||Insider||Buy||4,000||$33.98||$135,920.00|| |
|5/31/2017||James B. Hawkins||Insider||Buy||6,000||$33.81||$202,860.00|| |
|5/25/2017||Doris Engibous||Director||Sell||5,000||$32.68||$163,400.00|| |
|2/9/2017||Robert A Gunst||Director||Sell||5,000||$36.00||$180,000.00|| |
|12/16/2016||James B Hawkins||Insider||Buy||10,000||$35.20||$352,000.00|| |
|10/27/2016||James B Hawkins||Insider||Buy||10,000||$38.30||$383,000.00|| |
|10/25/2016||Jonathan Kennedy||CFO||Sell||30,276||$41.40||$1,253,426.40|| |
|10/24/2016||Jonathan Kennedy||CFO||Sell||14,138||$41.61||$588,282.18|| |
|10/24/2016||Robert A Gunst||Director||Sell||3,250||$41.92||$136,240.00|| |
|9/28/2016||James B Hawkins||Insider||Buy||10,000||$38.48||$384,800.00|| |
|4/26/2016||Robert A Gunst||Director||Sell||5,000||$34.61||$173,050.00|| |
|4/22/2016||Doris Engibous||Director||Sell||5,000||$32.68||$163,400.00|| |
|4/22/2016||Kenneth M Traverso||VP||Sell||7,459||$33.56||$250,324.04|| |
|2/17/2016||Ken Ludlum||Director||Sell||6,625||$33.02||$218,757.50|| |
|12/9/2015||Dong Chune Christopher Chung||VP||Sell||14,000||$48.78||$682,920.00|| |
|11/27/2015||James B. Hawkins||CEO||Sell||57,511||$49.09||$2,823,214.99|| |
|11/25/2015||Austin Francis Noll III||VP||Sell||38,875||$48.40||$1,881,550.00|| |
|11/12/2015||James B. Hawkins||CEO||Sell||42,489||$47.62||$2,023,326.18|| |
|10/30/2015||James B. Hawkins||CEO||Sell||100,000||$45.75||$4,575,000.00|| |
|10/28/2015||Dong Chune Christopher Chung||VP||Sell||26,000||$45.73||$1,188,980.00|| |
|10/28/2015||Jonathan Kennedy||CFO||Sell||28,958||$45.72||$1,323,959.76|| |
|9/15/2015||William M Moore||Director||Sell||5,994||$40.76||$244,315.44|| |
|9/14/2015||William M Moore||Director||Sell||4,000||$40.27||$161,080.00|| |
|9/8/2015||William M Moore||Director||Sell||3,006||$40.09||$120,510.54|| |
|8/18/2015||William M Moore||Director||Sell||3,000||$45.62||$136,860.00|| |
|8/13/2015||William M Moore||Director||Sell||4,000||$45.55||$182,200.00|| |
|7/24/2015||Robert A Gunst||Director||Sell||4,000||$45.30||$181,200.00|| |
|6/15/2015||William M Moore||Director||Sell||6,000||$41.30||$247,800.00|| |
|6/8/2015||James B Hawkins||CEO||Sell||100,000||$42.08||$4,208,000.00|| |
|6/3/2015||Dong Chune Christopher Chung||VP||Sell||26,000||$41.01||$1,066,260.00|| |
|4/28/2015||Kenneth M Traverso||VP||Sell||57,233||$40.80||$2,335,106.40|| |
|4/24/2015||Doris Engibous||Director||Sell||15,000||$42.20||$633,000.00|| |
|2/3/2015||Dong Chune Christopher Chung||VP||Sell||40,000||$36.64||$1,465,600.00|| |
|12/9/2014||Jonathan Kennedy||CFO||Sell||45,833||$35.67||$1,634,863.11|| |
|12/8/2014||William M Moore||Director||Sell||4,451||$34.65||$154,227.15|| |
|12/5/2014||William M Moore||Director||Sell||561||$34.65||$19,438.65|| |
|12/2/2014||William M Moore||Director||Sell||2,278||$3,478.00||$7,922,884.00|| |
|11/4/2014||James B Hawkins||CEO||Sell||18,400||$34.10||$627,440.00|| |
|10/30/2014||Robert A Gunst||Director||Sell||15,000||$33.92||$508,800.00|| |
|10/28/2014||Dong Chune Christopher Chung||VP||Sell||50,000||$33.14||$1,657,000.00|| |
|10/28/2014||James B Hawkins||CEO||Sell||251,600||$33.31||$8,380,796.00|| |
|10/27/2014||Dong Chune Christopher Chung||VP||Sell||39,521||$33.09||$1,307,749.89|| |
|10/24/2014||Kenneth M Traverso||VP||Sell||30,000||$33.33||$999,900.00|| |
|9/10/2014||William M Moore||Director||Sell||2,200||$29.30||$64,460.00|| |
|9/8/2014||William M Moore||Director||Sell||5,000||$29.17||$145,850.00|| |
|7/30/2014||Austin Francis Noll III||VP||Sell||23,500||$29.42||$691,370.00|| |
|5/30/2014||Ken Ludlum||Director||Sell||2,500||$24.77||$61,925.00|| |
|2/24/2014||James Hawkins||CEO||Sell||75,000||$25.88||$1,941,000.00|| |
|2/13/2014||James Hawkins||CEO||Sell||96,046||$24.77||$2,379,059.42|| |
|2/4/2014||James Hawkins||CEO||Sell||16,910||$25.93||$438,476.30|| |
|12/4/2013||James Hawkins||CEO||Sell||206,878||$22.58||$4,671,305.24|| |
|10/29/2013||Kenneth M Traverso||VP||Sell||25,000||$19.54||$488,500.00|| |
|9/12/2013||Doris Engibous||Director||Sell||33,750||$13.53||$456,637.50|| |
|9/12/2013||Kenneth M Traverso||VP||Sell||4,225||$13.89||$58,685.25|| |
|8/19/2013||Dong Chune Christopher Chung||VP||Sell||5,818||$12.78||$74,354.04|| |
|8/19/2013||James Hawkins||CEO||Sell||22,190||$12.78||$283,588.20|| |
|6/5/2013||Kenneth M Traverso||VP||Sell||22,682||$14.30||$324,352.60|| |
|6/3/2013||Kenneth M Traverso||VP||Sell||7,318||$14.50||$106,111.00|| |
|5/28/2013||Steven J Murphy||VP||Sell||10,000||$14.42||$144,200.00|| |
|3/12/2013||Robert A Gunst||Director||Buy||5,000||$13.40||$67,000.00|| |
|11/27/2012||Robert A Gunst||Director||Buy||10,000||$11.66||$116,600.00|| |
|11/9/2012||Kenneth M Traverso||VP||Sell||49,885||$11.19||$558,213.15|| |
Headline Trends for Natus Medical Incorporated (NASDAQ:BABY)
Latest Headlines for Natus Medical Incorporated (NASDAQ:BABY)
Loading headlines, please wait.
Natus Medical Incorporated (BABY) Chart for Monday, October, 23, 2017